Nav: Home

St. Jude research will guide development of new anti-influenza drugs

March 14, 2016

By analyzing the molecular details of how artificially created drug-resistant flu strains manage to survive treatment, St. Jude Children's Research Hospital scientists have developed insights to guide development of powerful new anti-influenza drugs. These compounds will target a viral enzyme critical to the virus' proliferation in the body.

The researchers published their findings today in the Proceedings of the National Academy of Sciences (PNAS). They were led by Richard Webby, Ph.D., a member of the St. Jude Department of Infectious Diseases, and Stephen White, D.Phil., chair of the St. Jude Department of Structural Biology.

Developing new anti-influenza drugs is critical because they are the only weapons that can initially battle an outbreak of new flu strains.

"It may take six months or more from identifying a new strain to actually having a vaccine specific to that strain," Webby said. "What's more, even a vaccine for the seasonal flu may be only 50 to 75 percent effective." Such an effectiveness gap may arise because new strains may appear after flu epidemiologists have decided which strains of the virus to target with the vaccine for a given flu season.

New anti-flu drugs are also needed because existing drugs aim at targets in the virus which could change or have already done so, creating resistant forms of viruses.

In their studies, the researchers explored how a highly promising class of anti-influenza drug targets a bit of viral machinery, called an endonuclease, essential for the virus to replicate. The endonuclease helps "disguise" viral genetic material to fool the infected cell into generating new virus.

The researchers analyzed how a prototype anti-flu drug called L-742,001 plugs into the critical functional region of the endonuclease, called the active site, to block its function. Investigators chose L-742,001 because it is a gangly molecule that attaches to the active site in many places. Thus, the researchers could explore many avenues to resistance--studying how the virus might mutate to alter the active site in different places.

In their first experiments, the researchers got some good news. The scientists found that the virus could not evolve resistance to L-742,001 when researchers exposed successive generations of the virus to the drug--as might happen in clinical use of the drug.

"This finding is an encouraging sign that under natural conditions the virus may not readily become resistant to this class of drug," Webby said.

Unable to induce the flu virus to naturally become drug-resistant, the researchers resorted to creating artificially resistant strains. The investigators produced viruses with mutations throughout the endonuclease protein and selected mutated viral strains that could survive the drug's onslaught. Then, Stephen White, D.Phil., and his colleagues analyzed the structure of those mutations.

That structural analysis of the resistant mutations established that drugs like L-742,001 actually targeted the endonuclease active site.

"We introduced mutations all over the molecule, but only those at the active site produced resistance," White said.

More specifically, the mutation studies identified regions of the active site that the virus could potentially mutate to evolve resistance to the L-742,001 class of drugs. This insight will help guide co-corresponding author Thomas Webb, Ph.D., of SRI International, who has been leading the synthesis of new drug molecules that don't plug into such regions, to avoid such potential resistance. White said progress has already been made in making improved anti-influenza drug candidates.

"We already have molecules that bind to the active site much, much better than L-742,001, and stay away from one of the pockets that could evolve resistance," White said. "And these findings give us more insight into designing drugs that avoid that region."

The researchers issued one caution: although the flu virus exposed to the drug did not naturally evolve resistance, it could develop resistance under continued "drug pressure."

"For example," Webby said, "the virus might develop and maintain resistance in the context of a family where multiple people are using such a drug." However, he added: "Our study suggests that these resistant mutants probably can't compete with natural viruses but by keeping the drug pressure on they do have the advantage."

White said anti-viral drug research in general could benefit from the St. Jude approach to artificially generating resistant mutants and analyzing their structure.

"It's certainly quite important that researchers perform the standard experiments of exposing a virus to drugs to see if resistance develops," White said. "But this technique of generating mutants adds an important new dimension that enables researchers to confirm the targets of antivirals and to further probe the nature of potential resistance."
-end-
The study's other authors are Min-Suk Song, formerly of St. Jude and now at Chungbuk University, South Korea; Sun-Woo Yoon, formerly of St. Jude and now at Korea Research Institute of Bioscience and Biotechnology, South Korea; Trushar Jeevan, Thomas Fabrizio, Gyanendra Kumar, Zhenmei Li, William Shadrick and Peter Slavish, all of St. Jude; and Wei Zhou of SRI International.

The research was supported by a grant (AI098757) from the National Institutes of Health (NIH); a grant (CA21765) from the National Cancer Institute, part of the NIH; contracts (HHSN266200700005C, HHSN272201400006C) from the National Institute of Allergy and Infectious Diseases, part of the NIH; and ALSAC.

St. Jude Children's Research Hospital

Related Virus Articles:

New insights into how the Zika virus causes microcephaly
Scientists have uncovered why Zika virus may specifically target neural stem cells in the developing brain, potentially leading to microcephaly.
New Zika virus inhibitor identified
Compound could serve as basis for drugs to prevent neurological complications of Zika.
Zeroing in on the Zika virus
Hobman has been announced as one of three Canadian scientists who have received funding from the Canadian Institutes of Health Research (CIHR) for their teams to study the Zika virus.
What does it take for an AIDS virus to infect a person?
Researchers examined the characteristics of HIV-1 strains that were successful in traversing the genital mucosa that forms a boundary to entry by viruses and bacteria.
Cough virus kills liver cancer cells and hepatitis virus
A virus that causes childhood coughs and colds could help in the fight against primary liver cancer, according to a study.
Characterizing the Zika virus genome
The sudden emergence of the Zika virus epidemic in Latin America in 2015-16 has caught the scientific world unawares.
Discovery of new Hepatitis C virus mechanism
Researchers at Osaka University, Japan uncovered the mechanisms that suppress the propagation of the hepatitis C virus with the potential of improving pathological liver conditions.
What does Zika virus mean for the children of the Americas?
A special communication article published online by JAMA Pediatrics explores whether new paradigms in child health may emerge because of Zika virus.
Predicting the spread of the Zika virus
A new tool by Japan-based researchers predicts the risk of Zika virus importation and local transmission for 189 countries.
An old new weapon against emerging Chikungunya virus
Researchers utilize existing drugs to interfere with host factors required for replication of Chikungunya virus.

Related Virus Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Bias And Perception
How does bias distort our thinking, our listening, our beliefs... and even our search results? How can we fight it? This hour, TED speakers explore ideas about the unconscious biases that shape us. Guests include writer and broadcaster Yassmin Abdel-Magied, climatologist J. Marshall Shepherd, journalist Andreas Ekström, and experimental psychologist Tony Salvador.
Now Playing: Science for the People

#513 Dinosaur Tails
This week: dinosaurs! We're discussing dinosaur tails, bipedalism, paleontology public outreach, dinosaur MOOCs, and other neat dinosaur related things with Dr. Scott Persons from the University of Alberta, who is also the author of the book "Dinosaurs of the Alberta Badlands".